FDA Approved: INLYTA — Supplemental Application (U.S. Pharmaceuticals)

View source ↗

Summary

FDA approved a supplemental application for INLYTA (axitinib) submitted by U.S. Pharmaceuticals. This action updates the drug’s labeling for renal cell carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)

Snippet

SUPPL AP for INLYTA (AXITINIB)